Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Impact of KRAS mutation variants on clinicopathological features and outcomes in patients with metastatic pancreatic adenocarcinoma.
Authors
Chirag Patel
Atrium Health, Charlotte, NC;
Chirag Patel , Wei Sha , Mohamed E. Salem , Laura W. Musselwhite , Jimmy J. Hwang , Kunal C. Kadakia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 749)
DOI
10.1200/JCO.2023.41.4_suppl.749
Abstract #
749
Poster Bd #
M16
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Clinicopathologic features of patients with KRAS wild-type pancreatic adenocarcinoma.
First Author: Mohamed E. Salem
Poster
2022 ASCO Gastrointestinal Cancers Symposium
The prevalence of common KRAS variants and associated outcomes in patients with metastatic colorectal cancer (mCRC).
First Author: Laura W. Musselwhite
Poster
2022 ASCO Gastrointestinal Cancers Symposium
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.
First Author: Tanios S. Bekaii-Saab
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Molecular precision medicine in pancreatic cancer: A single-center experience.
First Author: Anthony Tarabay